mTOR and its tight regulation for iNKT cell development and effector function

Molecular Immunology

Volumn 68, Issue 2, 2015, Pages 536-545

  Yang, Wei ^a   Gorentla, Balachandra ^b   Zhong, Xiao Ping ^b   Shin, Jinwook ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Inha University School of Medicine   (South Korea)

Author keywords

CARMA1; Diacylglycerol kinases; INKT cell; INKT1; INKT17; INKT2; MTOR; PTEN; Raptor; Ras; RasGRP1; Rictor; Signal transduction; TSC1 2

Indexed keywords

ADENYLATE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; COMPLEX FORMATION; EFFECTOR CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NATURAL KILLER T CELL;

ANIMALS; CELL DIFFERENTIATION; HUMANS; LYMPHOCYTE ACTIVATION; NATURAL KILLER T-CELLS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84949113513     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.07.022     Document Type: Article

References (144)

1. Avruch J., Hara K., Lin Y., Liu M., Long X., Ortiz-Vega S., Yonezawa K. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 2006, 25:6361-6372.
2. Bateup H.S., Takasaki K.T., Saulnier J.L., Denefrio C.L., Sabatini B.L. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J. Neurosci. 2011, 31:8862-8869.
3. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25:297-336.
4. Benhamron S., Tirosh B. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation and loss of marginal zone B cells. Eur. J. Immunol. 2011, 41:2390-2396.
5. Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013, 339:1323-1328.
6. Berzins S.P., Ritchie D.S. Natural killer T cells: drivers or passengers in preventing human disease?. Nat. Rev. Immunol. 2014, 14:640-646.
7. Biburger M., Tiegs G. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J. Immunol. 2005, 175:1540-1550.
8. Brennan P.J., Brigl M., Brenner M.B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 2013, 13:101-117.
9. Byles V., Covarrubias A.J., Ben-Sahra I., Lamming D.W., Sabatini D.M., Manning B.D., Horng T. The TSC-mTOR pathway regulates macrophage polarization. Nat. Commun. 2013, 4:2834.
10. Cai S.L., Tee A.R., Short J.D., Bergeron J.M., Kim J., Shen J., Guo R., Johnson C.L., Kiguchi K., Walker C.L. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J. Cell Biol. 2006, 173:279-289.
11. Cantorna M.T., Zhao J., Yang L. Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. Proc. Nutr. Soc. 2012, 71:62-66.
12. Caron E., Ghosh S., Matsuoka Y., Ashton-Beaucage D., Therrien M., Lemieux S., Perreault C., Roux P.P., Kitano H. A comprehensive map of the mTOR signaling network. Mol. Syst. Biol. 2010, 6:453.
13. Chang W.S., Kim J.Y., Kim Y.J., Kim Y.S., Lee J.M., Azuma M., Yagita H., Kang C.Y. Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J. Immunol. 2008, 181:6707-6710.
14. Chang P.P., Barral P., Fitch J., Pratama A., Ma C.S., Kallies A., Hogan J.J., Cerundolo V., Tangye S.G., Bittman R., Nutt S.L., Brink R., Godfrey D.I., Batista F.D., Vinuesa C.G. Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat. Immunol. 2012, 13:35-43.
15. Choo A.Y., Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009, 8:567-572.
16. Chung B., Aoukaty A., Dutz J., Terhorst C., Tan R. Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J. Immunol. 2005, 174:3153-3157.
17. Ci X., Kuraoka M., Wang H., Carico Z., Hopper K., Shin J., Deng X., Qiu Y., Unniraman S., Kelsoe G., Zhong X.P. TSC1 promotes B cell maturation but is dispensable for germinal center formation. PLoS One 2015, 10:e0127527.
18. Constantinides M.G., Bendelac A. Transcriptional regulation of the NKT cell lineage. Curr. Opin. Immunol. 2013, 25:161-167.
19. Coquet J.M., Chakravarti S., Kyparissoudis K., McNab F.W., Pitt L.A., McKenzie B.S., Berzins S.P., Smyth M.J., Godfrey D.I. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11287-11292.
20. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., Kaneko Y., Koseki H., Kanno M., Taniguchi M. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997, 278:1623-1626.
21. Delgoffe G.M., Kole T.P., Zheng Y., Zarek P.E., Matthews K.L., Xiao B., Worley P.F., Kozma S.C., Powell J.D. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844.
22. Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., Xiao B., Worley P.F., Powell J.D. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 2011, 12:295-303.
23. DeYoung M.P., Horak P., Sofer A., Sgroi D., Ellisen L.W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008, 22:239-251.
24. Dubinsky A.N., Dastidar S.G., Hsu C.L., Zahra R., Djakovic S.N., Duarte S., Esau C.C., Spencer B., Ashe T.D., Fischer K.M., MacKenna D.A., Sopher B.L., Masliah E., Gaasterland T., Chau B.N., Pereira de Almeida L., Morrison B.E., La Spada A.R. Let-7 coordinately suppresses components of the amino acid sensing pathway to repress mTORC1 and induce autophagy. Cell Metab. 2014, 20:626-638.
25. Fingar D.C., Salama S., Tsou C., Harlow E., Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002, 16:1472-1487.
26. Finlay D.K., Kelly A.P., Clarke R., Sinclair L.V., Deak M., Alessi D.R., Cantrell D.A. Temporal differences in the dependency on phosphoinositide-dependent kinase 1 distinguish the development of invariant Valpha14 NKT cells and conventional T cells. J. Immunol. 2010, 185:5973-5982.
27. Gapin L., Matsuda J.L., Surh C.D., Kronenberg M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat. Immunol. 2001, 2:971-978.
28. Godfrey D.I., Stankovic S., Baxter A.G. Developing NKT cells need their calcium. Nat. Immunol. 2009, 10:231-233.
29. Godfrey D.I., Stankovic S., Baxter A.G. Raising the NKT cell family. Nat. Immunol. 2010, 11:197-206.
30. Gordy L.E., Bezbradica J.S., Flyak A.I., Spencer C.T., Dunkle A., Sun J., Stanic A.K., Boothby M.R., He Y.W., Zhao Z., Van Kaer L., Joyce S. IL-15 regulates homeostasis and terminal maturation of NKT cells. J. Immunol. 2011, 187:6335-6345.
31. Gorentla B.K., Zhong X.P. T cell receptor signal transduction in T lymphocytes. J. Clin. Cell Immunol. 2012, 2012:5.
32. Gorentla B.K., Wan C.K., Zhong X.P. Negative regulation of mTOR activation by diacylglycerol kinases. Blood 2011, 117:4022-4031.
33. Griewank K., Borowski C., Rietdijk S., Wang N., Julien A., Wei D.G., Mamchak A.A., Terhorst C., Bendelac A. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. Immunity 2007, 27:751-762.
34. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006, 11:859-871.
35. Guo R., Wan C.K., Carpenter J.H., Mousallem T., Boustany R.M., Kuan C.T., Burks A.W., Zhong X.P. Synergistic control of T cell development and tumor suppression by diacylglycerol kinase alpha and zeta. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11909-11914.
36. Hamilton K.S., Phong B., Corey C., Cheng J., Gorentla B., Zhong X., Shiva S., Kane L.P. T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10. Sci. Signal. 2014, 7:ra55.
37. Henao-Mejia J., Williams A., Goff L.A., Staron M., Licona-Limon P., Kaech S.M., Nakayama M., Rinn J.L., Flavell R.A. The MicroRNA miR-181 Is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity 2013, 38:984-997.
38. Hong C., Park S.H. Application of natural killer T cells in antitumor immunotherapy. Crit. Rev. Immunol. 2007, 27:511-525.
39. Hu T., Gimferrer I., Simmons A., Wiest D., Alberola-Ila J. The Ras/MAPK pathway is required for generation of iNKT cells. PLoS One 2011, 6:e19890.
40. Huang J., Manning B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 2008, 412:179-190.
41. Huang J., Manning B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 2009, 37:217-222.
42. Huang J.R., Tsai Y.C., Chang Y.J., Wu J.C., Hung J.T., Lin K.H., Wong C.H., Yu A.L. alpha-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3. J. Immunol. 2014, 192:1972-1981.
43. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
44. Inui T., Nakashima H., Habu Y., Nakagawa R., Fukasawa M., Kinoshita M., Shinomiya N., Seki S. Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice. J. Hepatol. 2005, 43:670-678.
45. Iyoda T., Ushida M., Kimura Y., Minamino K., Hayuka A., Yokohata S., Ehara H., Inaba K. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. Int. Immunol. 2010, 22:905-913.
46. Jin Y., Qu S., Tesikova M., Wang L., Kristian A., Maelandsmo G.M., Kong H., Zhang T., Jeronimo C., Teixeira M.R., Yuca E., Tekedereli I., Gorgulu K., Alpay N., Sood A.K., Lopez-Berestein G., Danielsen H.E., Ozpolat B., Saatcioglu F. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E2572-E2581.
47. Johnson S.C., Rabinovitch P.S., Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013, 493:338-345.
48. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
49. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
50. Kishimoto H., Ohteki T., Yajima N., Kawahara K., Natsui M., Kawarasaki S., Hamada K., Horie Y., Kubo Y., Arase S., Taniguchi M., Vanhaesebroeck B., Mak T.W., Nakano T., Koyasu S., Sasaki T., Suzuki A. The Pten/PI3K pathway governs the homeostasis of Valpha14iNKT cells. Blood 2007, 109:3316-3324.
51. Kleinewietfeld M., Manzel A., Titze J., Kvakan H., Yosef N., Linker R.A., Muller D.N., Hafler D.A. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013, 496:518-522.
52. Kojo S., Elly C., Harada Y., Langdon W.Y., Kronenberg M., Liu Y.C. Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17847-17851.
53. Kovalovsky D., Uche O.U., Eladad S., Hobbs R.M., Yi W., Alonzo E., Chua K., Eidson M., Kim H.J., Im J.S., Pandolfi P.P., Sant'Angelo D.B. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat. Immunol. 2008, 9:1055-1064.
54. Krishna S., Zhong X. Role of diacylglycerol kinases in T cell development and function. Crit. Rev. Immunol. 2013, 33:97-118.
55. Laplante M., Sabatini D.M. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 2009, 19:R1046-R1052.
56. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
57. Lazarevic V., Zullo A.J., Schweitzer M.N., Staton T.L., Gallo E.M., Crabtree G.R., Glimcher L.H. The gene encoding early growth response 2, a target of the transcription factor NFAT, is required for the development and maturation of natural killer T cells. Nat. Immunol. 2009, 10:306-313.
58. Lazarevic V., Glimcher L.H., Lord G.M. T-bet: a bridge between innate and adaptive immunity. Nat. Rev. Immunol. 2013, 13:777-789.
59. Lee D.F., Kuo H.P., Chen C.T., Hsu J.M., Chou C.K., Wei Y., Sun H.L., Li L.Y., Ping B., Huang W.C., He X., Hung J.Y., Lai C.C., Ding Q., Su J.L., Yang J.Y., Sahin A.A., Hortobagyi G.N., Tsai F.J., Tsai C.H., Hung M.C. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130:440-455.
60. Lee K., Gudapati P., Dragovic S., Spencer C., Joyce S., Killeen N., Magnuson M.A., Boothby M. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010, 32:743-753.
61. Lee Y.J., Holzapfel K.L., Zhu J., Jameson S.C., Hogquist K.A. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat. Immunol. 2013, 14:1146-1154.
62. Li S., Miao T., Sebastian M., Bhullar P., Ghaffari E., Liu M., Symonds A.L., Wang P. The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells. Immunity 2012, 37:685-696.
63. Lynch L., Michelet X., Zhang S., Brennan P.J., Moseman A., Lester C., Besra G., Vomhof-Dekrey E.E., Tighe M., Koay H.F., Godfrey D.I., Leadbetter E.A., Sant'Angelo D.B., von Andrian U., Brenner M.B. Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of T(reg) cells and macrophages in adipose tissue. Nat. Immunol. 2015, 16:85-95.
64. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10:307-318.
65. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
66. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., Koezuka Y., Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 2000, 192:741-754.
67. Matsuda J.L., Gapin L., Sidobre S., Kieper W.C., Tan J.T., Ceredig R., Surh C.D., Kronenberg M. Homeostasis of V alpha 14i NKT cells. Nat. Immunol. 2002, 3:966-974.
68. Matsuda J.L., Zhang Q., Ndonye R., Richardson S.K., Howell A.R., Gapin L. T-bet concomitantly controls migration, survival, and effector functions during the development of Valpha14i NKT cells. Blood 2006, 107:2797-2805.
69. McEwen-Smith R.M., Salio M., Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immnuol. Res. 2015, 3:425-435.
70. Medoff B.D., Sandall B.P., Landry A., Nagahama K., Mizoguchi A., Luster A.D., Xavier R.J. Differential requirement for CARMA1 in agonist-selected T-cell development. Eur. J. Immunol. 2009, 39:78-84.
71. Mendiratta S.K., Martin W.D., Hong S., Boesteanu A., Joyce S., Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 1997, 6:469-477.
72. Michel M.L., Keller A.C., Paget C., Fujio M., Trottein F., Savage P.B., Wong C.H., Schneider E., Dy M., Leite-de-Moraes M.C. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J. Exp. Med. 2007, 204:995-1001.
73. Michel M.L., Mendes-da-Cruz D., Keller A.C., Lochner M., Schneider E., Dy M., Eberl G., Leite-de-Moraes M.C. Critical role of ROR-gammat in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:19845-19850.
74. Milpied P., Massot B., Renand A., Diem S., Herbelin A., Leite-de-Moraes M., Rubio M.T., Hermine O. IL-17-producing invariant NKT cells in lymphoid organs are recent thymic emigrants identified by neuropilin-1 expression. Blood 2011, 118:2993-3002.
75. Nichols K.E., Hom J., Gong S.Y., Ganguly A., Ma C.S., Cannons J.L., Tangye S.G., Schwartzberg P.L., Koretzky G.A., Stein P.L. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat. Med. 2005, 11:340-345.
76. O'Brien T.F., Gorentla B.K., Xie D., Srivatsan S., McLeod I.X., He Y.W., Zhong X.P. Regulation of T-cell survival and mitochondrial homeostasis by TSC1. Eur. J. Immunol. 2011, 41:3361-3370.
77. Olenchock B.A., Guo R., Carpenter J.H., Jordan M., Topham M.K., Koretzky G.A., Zhong X.P. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat. Immunol. 2006, 7:1174-1181.
78. Osman Y., Kawamura T., Naito T., Takeda K., Van Kaer L., Okumura K., Abo T. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur. J. Immunol. 2000, 30:1919-1928.
79. Pages F., Ragueneau M., Rottapel R., Truneh A., Nunes J., Imbert J., Olive D. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994, 369:327-329.
80. Pan H., O'Brien T.F., Zhang P., Zhong X.P. The role of tuberous sclerosis complex 1 in regulating innate immunity. J. Immunol. 2012, 188:3658-3666.
81. Pan H., O'Brien T.F., Wright G., Yang J., Shin J., Wright K.L., Zhong X.P. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. J. Immunol. 2013, 191:699-707.
82. Parekh V.V., Wilson M.T., Olivares-Villagomez D., Singh A.K., Wu L., Wang C.R., Joyce S., Van Kaer L. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 2005, 115:2572-2583.
83. Parekh V.V., Lalani S., Kim S., Halder R., Azuma M., Yagita H., Kumar V., Wu L., Kaer L.V. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J. Immunol. 2009, 182:2816-2826.
84. Park H., Tsang M., Iritani B.M., Bevan M.J. Metabolic regulator Fnip1 is crucial for iNKT lymphocyte development. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:7066-7071.
85. Pasquier B., Yin L., Fondaneche M.C., Relouzat F., Bloch-Queyrat C., Lambert N., Fischer A., de Saint-Basile G., Latour S. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J. Exp. Med. 2005, 201:695-701.
86. Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S., Sabatini D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
87. Peterson T.R., Sengupta S.S., Harris T.E., Carmack A.E., Kang S.A., Balderas E., Guertin D.A., Madden K.L., Carpenter A.E., Finck B.N., Sabatini D.M. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146:408-420.
88. Pobezinsky L.A., Etzensperger R., Jeurling S., Alag A., Kadakia T., McCaughtry T.M., Kimura M.Y., Sharrow S.O., Guinter T.I., Feigenbaum L., Singer A. Let-7 microRNAs target the lineage-specific transcription factor PLZF to regulate terminal NKT cell differentiation and effector function. Nat. Immunol. 2015, 10.1038/ni.3146.
89. Pollizzi K.N., Powell J.D. Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol. 2015, 36:13-20.
90. Prevot N., Pyaram K., Bischoff E., Sen J.M., Powell J.D., Chang C.H. Mammalian target of rapamycin complex 2 regulates invariant NKT cell development and function independent of promyelocytic leukemia zinc-finger. J. Immunol. 2015, 194:223-230.
91. Rampuria P., Lang M.L. CD1d-dependent expansion of NKT follicular helper cells in vivo and in vitro is a product of cellular proliferation and differentiation. Int. Immunol. 2015, 27:253-263.
92. Ranson T., Vosshenrich C.A., Corcuff E., Richard O., Laloux V., Lehuen A., Di Santo J.P. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2663-2668.
93. Renukaradhya G.J., Khan M.A., Vieira M., Du W., Gervay-Hague J., Brutkiewicz R.R. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008, 111:5637-5645.
94. Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L., Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 2013, 339:1320-1323.
95. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13489-13494.
96. Sag D., Krause P., Hedrick C.C., Kronenberg M., Wingender G. IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset. J. Clin. Invest. 2014, 124:3725-3740.
97. Salio M., Silk J.D., Jones E.Y., Cerundolo V. Biology of CD1- and MR1-restricted T cells. Annu. Rev. Immunol. 2014, 32:323-366.
98. Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141:290-303.
99. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
100. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
101. Sathaliyawala T., O'Gorman W.E., Greter M., Bogunovic M., Konjufca V., Hou Z.E., Nolan G.P., Miller M.J., Merad M., Reizis B. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 2010, 33:597-606.
102. Savage A.K., Constantinides M.G., Han J., Picard D., Martin E., Li B., Lantz O., Bendelac A. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008, 29:391-403.
103. + regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4566-4571.
104. Seiler M.P., Mathew R., Liszewski M.K., Spooner C.J., Barr K., Meng F., Singh H., Bendelac A. Elevated and sustained expression of the transcription factors Egr1 and Egr2 controls NKT lineage differentiation in response to TCR signaling. Nat. Immunol. 2012, 13:264-271.
105. Shen S., Chen Y., Gorentla B.K., Lu J., Stone J.C., Zhong X.P. Critical roles of RasGRP1 for invariant NKT cell development. J. Immunol. 2011, 187:4467-4473.
106. Shen S., Wu J., Srivatsan S., Gorentla B.K., Shin J., Xu L., Zhong X.P. Tight regulation of diacylglycerol-mediated signaling is critical for proper invariant NKT cell development. J. Immunol. 2011, 187:2122-2129.
107. Shimobayashi M., Hall M.N. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat. Rev. Mol. Cell Biol. 2014, 15:155-162.
108. Shin J., Pan H., Zhong X.P. Regulation of mast cell survival and function by tuberous sclerosis complex 1. Blood 2012, 119:3306-3314.
109. Shin J., Wang S., Deng W., Wu J., Gao J., Zhong X.P. Mechanistic target of rapamycin complex 1 is critical for invariant natural killer T-cell development and effector function. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E776-E783.
110. Sivakumar V., Hammond K.J., Howells N., Pfeffer K., Weih F. Differential requirement for Rel/nuclear factor kappa B family members in natural killer T cell development. J. Exp. Med. 2003, 197:1613-1621.
111. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., Kawano T., Pelikan S.B., Crowe N.Y., Godfrey D.I. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000, 191:661-668.
112. Stanic A.K., Bezbradica J.S., Park J.J., Van Kaer L., Boothby M.R., Joyce S. Cutting edge: the ontogeny and function of Va14Ja18 natural T lymphocytes require signal processing by protein kinase C theta and NF-kappa B. J. Immunol. 2004, 172:4667-4671.
113. Stanic A.K., Bezbradica J.S., Park J.J., Matsuki N., Mora A.L., Van Kaer L., Boothby M.R., Joyce S. NF-kappa B controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J. Immunol. 2004, 172:2265-2273.
114. Teng M.W., Westwood J.A., Darcy P.K., Sharkey J., Tsuji M., Franck R.W., Porcelli S.A., Besra G.S., Takeda K., Yagita H., Kershaw M.H., Smyth M.J. Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res. 2007, 67:7495-7504.
115. Terashima A., Watarai H., Inoue S., Sekine E., Nakagawa R., Hase K., Iwamura C., Nakajima H., Nakayama T., Taniguchi M. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J. Exp. Med. 2008, 205:2727-2733.
116. Tonti E., Fedeli M., Napolitano A., Iannacone M., von Andrian U.H., Guidotti L.G., Abrignani S., Casorati G., Dellabona P. Follicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help. J. Immunol. 2012, 188:3217-3222.
117. Townsend M.J., Weinmann A.S., Matsuda J.L., Salomon R., Farnham P.J., Biron C.A., Gapin L., Glimcher L.H. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004, 20:477-494.
118. Uldrich A.P., Crowe N.Y., Kyparissoudis K., Pellicci D.G., Zhan Y., Lew A.M., Bouillet P., Strasser A., Smyth M.J., Godfrey D.I. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 2005, 175:3092-3101.
119. Van Kaer L., Parekh V.V., Wu L. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol. 2013, 34:50-58.
120. von Essen M.R., Kongsbak M., Schjerling P., Olgaard K., Odum N., Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat. Immunol. 2010, 11:344-349.
121. Wang Y., Huang G., Zeng H., Yang K., Lamb R.F., Chi H. Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E4894-E4903.
122. Watarai H., Sekine-Kondo E., Shigeura T., Motomura Y., Yasuda T., Satoh R., Yoshida H., Kubo M., Kawamoto H., Koseki H., Taniguchi M. Development and function of invariant natural killer T cells producing T(h)2- and T(h)17-cytokines. PLoS Biol. 2012, 10:e1001255.
123. Webster K.E., Kim H.O., Kyparissoudis K., Corpuz T.M., Pinget G.V., Uldrich A.P., Brink R., Belz G.T., Cho J.H., Godfrey D.I., Sprent J. IL-17-producing NKT cells depend exclusively on IL-7 for homeostasis and survival. Mucosal Immunol. 2014, 7:1058-1067.
124. Wei J., Yang K., Chi H. Cutting edge: discrete functions of mTOR signaling in invariant NKT cell development and NKT17 fate decision. J. Immunol. 2014, 193:4297-4301.
125. Wu Q., Liu Y., Chen C., Ikenoue T., Qiao Y., Li C.S., Li W., Guan K.L., Liu Y., Zheng P. The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. J. Immunol. 2011, 187:1106-1112.
126. Wu C., Yosef N., Thalhamer T., Zhu C., Xiao S., Kishi Y., Regev A., Kuchroo V.K. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013, 496:513-517.
127. Wu J., Shen S., Yang J., Xia Z., Zhong X.P. Diacylglycerol kinase zeta positively controls the development of iNKT-17 cells. PLoS One 2013, 8:e75202.
128. Wu J., Yang J., Yang K., Wang H., Gorentla B., Shin J., Qiu Y., Que L.G., Foster W.M., Xia Z., Chi H., Zhong X.P. iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions. J. Clin. Invest. 2014, 124:1685-1698.
129. Wu J., Shin J., Xie D., Wang H., Gao J., Zhong X.P. Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. J. Immunol. 2014, 192:2643-2650.
130. Xie D.L., Wu J., Lou Y.L., Zhong X.P. Tumor suppressor TSC1 is critical for T-cell anergy. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:14152-14157.
131. Yamasaki K., Horiguchi S., Kurosaki M., Kunii N., Nagato K., Hanaoka H., Shimizu N., Ueno N., Yamamoto S., Taniguchi M., Motohashi S., Nakayama T., Okamoto Y. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin. Immunol. 2011, 138:255-265.
132. Yang K., Neale G., Green D.R., He W., Chi H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat. Immunol. 2011, 12:888-897.
133. Yang K., Shrestha S., Zeng H., Karmaus P.W., Neale G., Vogel P., Guertin D.A., Lamb R.F., Chi H. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 2013, 39:1043-1056.
134. Yecies J.L., Zhang H.H., Menon S., Liu S., Yecies D., Lipovsky A.I., Gorgun C., Kwiatkowski D.J., Hotamisligil G.S., Lee C.H., Manning B.D. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 2011, 14:21-32.
135. Yu S., Cantorna M.T. The vitamin D receptor is required for iNKT cell development. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5207-5212.
136. Zarrouk M., Rolf J., Cantrell D.A. LKB1 mediates the development of conventional and innate T cells via AMP-dependent kinase autonomous pathways. PLoS One 2013, 8:e60217.
137. Zhang L., Tschumi B.O., Corgnac S., Ruegg M.A., Hall M.N., Mach J.P., Romero P., Donda A. Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function. J. Immunol. 2014, 193:1759-1765.
138. Zheng Y., Collins S.L., Lutz M.A., Allen A.N., Kole T.P., Zarek P.E., Powell J.D. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 2007, 178:2163-2170.
139. Zhong X.P., Hainey E.A., Olenchock B.A., Zhao H., Topham M.K., Koretzky G.A. Regulation of T cell receptor-induced activation of the Ras-ERK pathway by diacylglycerol kinase zeta. J. Biol. Chem. 2002, 277:31089-31098.
140. Zhong X.P., Hainey E.A., Olenchock B.A., Jordan M.S., Maltzman J.S., Nichols K.E., Shen H., Koretzky G.A. Enhanced T cell responses due to diacylglycerol kinase zeta deficiency. Nat. Immunol. 2003, 4:882-890.
141. Zhong X.P., Guo R., Zhou H., Liu C., Wan C.K. Diacylglycerol kinases in immune cell function and self-tolerance. Immunol. Rev. 2008, 224:249-264.
142. Zhu H., Shyh-Chang N., Segre A.V., Shinoda G., Shah S.P., Einhorn W.S., Takeuchi A., Engreitz J.M., Hagan J.P., Kharas M.G., Urbach A., Thornton J.E., Triboulet R., Gregory R.I., Consortium D., Investigators M., Altshuler D., Daley G.Q. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011, 147:81-94.
143. Zhu L., Yang T., Li L., Sun L., Hou Y., Hu X., Zhang L., Tian H., Zhao Q., Peng J., Zhang H., Wang R., Yang Z., Zhang L., Zhao Y. TSC1 controls macrophage polarization to prevent inflammatory disease. Nat. Commun. 2014, 5:4696.
144. Zietara N., Lyszkiewicz M., Witzlau K., Naumann R., Hurwitz R., Langemeier J., Bohne J., Sandrock I., Ballmaier M., Weiss S., Prinz I., Krueger A. Critical role for miR-181a/b-1 in agonist selection of invariant natural killer T cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:7407-7412.